Amicus Therapeutics: Devoted to the Ones Who Get Left Behind

Amicus Therapeutics was founded in 2002 and became a publicly shared company in 2006. Amicus Therapeutics is an American pharmaceutical company that has dedicated itself to treating rare and orphan diseases that severely affect small percentages of people all over the world. Among these diseases, Amicus Therapeutics particularly devotes their time and studies to a select group of 50 rare, devastating metabolic disorders. This group of 50 disorders is often referred to as lysosomal storage diseases or LSDs. Two major lysosomal storage diseases that Amicus Therapeutics specializes in are called Fabry disease and Pompe disease. Because these diseases are so rare patients suffering from them are often misdiagnosed for years leading to even more devastating effects. It is because of Amicus Therapeutics that these patients are not left behind, ignored, or misdiagnosed anymore. Besides focusing on Lysosomal storage diseases Amicus Therapeutics also works on developing enzyme replacement therapies often referred to as ERTs.

Amicus Therapeutics was originally founded in 2002 in New Jersey. The Chief Executive Officer or CEO title was eventually given to John F. Crowley in the year of 2005. The COO of Amicus is Bradley Campbell and the CFO is William Baird. It only took six years from being found for the company to expand from its humble New Jersey roots all the way to San Diego in 2008 in search of a second development center. A year later the company hit an unfortunate financial setback which eventually was saved because of an enormous 500,000 dollar grant from the Michael J. Fox Foundation in 2010. Along with the grant from the Michael J. Fox Foundation, Amicus Therapeutics also received a grant worth 210,300 dollars from the Alzheimer’s Drug Discovery Foundation to support preclinical work (Yahoo Finance). In their years of development and study Amicus Therapeutics has helped many patients overcome their hardships from these rare diseases.

More about Amicus Therapeutics at